# Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

> **NCT03436771** · — · TERMINATED · sponsor: **Juno Therapeutics, a Subsidiary of Celgene** · enrollment: 4 (actual)

## Conditions studied

- Non Hodgkin Lymphoma
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma

## Interventions

- **GENETIC:** JCAR017
- **GENETIC:** JCARH125

## Key facts

- **NCT ID:** NCT03436771
- **Lead sponsor:** Juno Therapeutics, a Subsidiary of Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-19
- **Primary completion:** 2018-07-20
- **Final completion:** 2018-07-20
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Eligible subjects will be enrolled in Celgene's long-term follow-up protocol for subjects previously treated with a CAR T-cell product.
- **Last updated:** 2020-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03436771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03436771, "Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03436771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*